Literature DB >> 22516144

Exposure keratopathy in sedated and ventilated patients.

Hisham Jammal1, Yousef Khader, Wisam Shihadeh, Laila Ababneh, Ghazal Aljizawi, Arqam AlQasem.   

Abstract

PURPOSE: The purpose of this study is to determine the frequency of exposure keratopathy in sedated/mechanically ventilated patients in the intensive care unit and its risk factors.
MATERIALS AND METHODS: This is a prospective cohort study including all patients admitted to an adult intensive care unit department between March and October 2010 who were sedated and mechanically ventilated. Patients were examined by an ophthalmologist 1 to 5 days after commencing ventilation and subsequently every day. Examination included assessment of lid position, conjunctival edema (chemosis), and corneal changes.
RESULTS: Of the 74 patients included in the study, 57% had exposure keratopathy. Fifty-four percent of patients developed chemosis, and 31% of patients developed lagophthalmos. Frequency of exposure keratopathy differed significantly according to degree of chemosis and lagophthalmos (P < .0001); lagophthalmos was also significantly related to chemosis (P < .0001). For lagophthalmos score of 3, the odds ratio of association with higher exposure keratopathy score was 136 (95% confidence interval [CI], 14.97-1242.6); for lagophthalmos score of 2, it was 14.4 (95% CI, 2.67-77.2). For any edema, the odds ratio of association with exposure keratopathy was 5.50 (95% CI, 2.02-15.00).
CONCLUSION: The frequency of exposure keratopathy in sedated/mechanically ventilated patients is high with lagophthalmos and chemosis as the main risk factors.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22516144     DOI: 10.1016/j.jcrc.2012.02.005

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  8 in total

Review 1.  COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations.

Authors:  Timothy P H Lin; Chung-Nga Ko; Ke Zheng; Kenny H W Lai; Raymond L M Wong; Allie Lee; Shaochong Zhang; Suber S Huang; Kelvin H Wan; Dennis S C Lam
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2021-11-24

2.  The Effects of Passive Blinking on Exposure Keratopathy among Patients in Intensive Care Units.

Authors:  Korosh Rezaei; Nazanin Amini; Reza Rezaei; Fatemeh Rafiei; Mehdi Harorani
Journal:  Iran J Nurs Midwifery Res       Date:  2022-03-14

Review 3.  Update on overview of ocular manifestations of COVID-19.

Authors:  Mitra Akbari; Maryam Dourandeesh
Journal:  Front Med (Lausanne)       Date:  2022-09-13

4.  Changes of Ocular Surface and the Inflammatory Response in a Rabbit Model of Short-Term Exposure Keratopathy.

Authors:  Chun-Ting Lai; Wei-Chieng Yao; Szu-Yuan Lin; Hsin-Yu Liu; Huai-Wen Chang; Fung-Rong Hu; Wei-Li Chen
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

5.  Prediction of risk and incidence of dry eye in critical patients.

Authors:  Diego Dias de Araújo; Natália Gherardi Almeida; Priscila Marinho Aleixo Silva; Nayara Souza Ribeiro; Andreza Werli-Alvarenga; Tânia Couto Machado Chianca
Journal:  Rev Lat Am Enfermagem       Date:  2016-05-17

6.  Incidence, risk factors and impact of protocolised care on exposure keratopathy in critically ill adults: a two-phase prospective cohort study.

Authors:  Obaid Kousha; Zubaid Kousha; Jonathan Paddle
Journal:  Crit Care       Date:  2018-01-16       Impact factor: 9.097

7.  Clinical indicators of dry eye severity nursing outcome in intensive care unit.

Authors:  Raffaela Patrícia da Silva Soares; Ana Paula Nunes de Lima Fernandes; Fabiane Rocha Botarelli; Jéssica Naiara de Medeiros Araújo; Jéssica de Araújo Olímpio; Allyne Fortes Vitor
Journal:  Rev Lat Am Enfermagem       Date:  2019-10-28

8.  Descemetocele and bilateral, severe Pseudomonas keratitis in an intensive care unit patient with Graves' orbitopathy: A case report.

Authors:  Yun Chen Hsieh; Chun-Chen Chen
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.